ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/JAK
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/JAK
8
trial(s) found.
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06079879
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea (
3543-006
)
LSD1 inhibitor
antimetabolite
+ JAK1/JAK2 inhibitor
Essential thrombocythaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05936359
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (
INCA-33989-101
)
JAK1/JAK2 inhibitor
anti-CALR monoclonal antibody
Myeloproliferative Neoplasm
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05037760
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis (
KER050-MF-301
)
JAK1/JAK2 inhibitor
modified ActRIIA ligand trap protein
Myelofibrosis
NSW
2139 - Concord - Concord Repatriation General Hospital
2485 - Tweed Heads - The Tweed Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04176198
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
Momelotinib
Ruxolitinib
cancer therapy
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
+ JAK1/JAK2 inhibitor
Myelofibrosis
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT03165734
Haem
Phase 3
Recruiting
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/μL)(
PACIFICA
)
JAK2 inhibitor
Myelofibrosis
Polycythemia vera
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6005 - West Perth - Perth Blood Institute
ACTRN12619001298101
Advanced
Phase 2
Not yet recruiting
A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas (
ASN-002-IL
)
SYK/JAK inhibitor
Cutaneous basal cell carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ JAK1/JAK2 inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Not yet recruiting (1)
Status unknown (1)
Recruitment Country and State
VIC (6)
NSW (5)
SA (5)
QLD (3)
WA (3)
NZ (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (2)
Phase 3 (3)
Trial Type
Haem (6)
Advanced (2)
Cancer Therapy Class
JAK1
88%
JAK2
88%
MDM2
13%
LSD1
13%
CALR
13%
JAK
13%
SYK
13%
ALK
13%
ATR
13%
BCR-ABL1
13%
CDK4
13%
CDK6
13%
CRAF
13%
EGFR
13%
FLT3
13%
KIT
13%
MET
13%
PDGFR
13%
PDGFRA
13%
PI3K
13%
RAF
13%
ROS1
13%
SMO
13%
SRC
13%
VEGFR
13%
YES1
13%
mTOR
13%
mTORC1
13%
mTORC2
13%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
3004 - Melbourne, Southbank - Alfred Health (3)
3168 - Clayton - Monash Medical Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2217 - Kogarah - St George Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
Cancer Type
Cancer
Haematological malignancy
Myeloproliferative neoplasm
Myelofibrosis
Solid tumour
Essential thrombocythaemia
Polycythemia vera
Cutaneous basal cell carcinoma
Non-melanoma skin cancer
Skin cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy